Eli Lilly and Company / Avid Radiopharmaceuticals, Inc.

Alzheimer's Disease (Diagnostic Imaging)

Disease Overview

Alzheimer's disease is a progressive neurodegenerative disorder defined neuropathologically by beta-amyloid plaques and tau tangles. In 2010 it affected roughly 5.4M Americans, but definitive diagnosis required postmortem confirmation — leaving a major unmet need for in-vivo biomarkers to enable earlier and more accurate diagnosis.

Competitive Landscape

When Lilly bought Avid in November 2010, the only validated amyloid imaging tracer was Pittsburgh Compound B (¹¹C-PIB), constrained to research use by carbon-11's 20-minute half-life that prevented offsite distribution. Avid's florbetapir used fluorine-18 (109-minute half-life), enabling regional cyclotron-to-clinic logistics — a structural advantage that defined the commercial category. The competitive set quickly emerged: GE Healthcare's flutemetamol (Vizamyl, FDA-approved Oct 2013) and Bayer/Piramal's florbetaben (Neuraceq, FDA-approved March 2014) followed Amyvid (FDA-approved April 2012) into a three-way ¹⁸F-amyloid tracer market). Adoption was bottlenecked by CMS's 2013 non-coverage decision (CED only) and the lack of disease-modifying therapies for which an amyloid scan would change management — limiting clinical uptake despite strong diagnostic performance. The category was reanimated by Biogen/Eisai's aducanumab (Aduhelm, 2021) and lecanemab (Leqembi, 2023) anti-amyloid antibodies, which require amyloid PET or CSF confirmation for treatment eligibility — finally turning Amyvid and competitors into companion diagnostics for a real therapeutic decision. Lilly's $300M upfront / $500M milestone structure proved prescient given that ~12-year delay to commercial inflection.